The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

See privacy policy. [LIMA, PERU] Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, ...

Although it is less virulent than HIV-1, some HIV medications do not work as well against this type of HIV. HIV-1 is thought ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

By Chris Ayeko, FNP Pre-exposure Prophylaxis (PrEP) is a highly effective medication that prevents virus replication, ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Study looked at 198 kidney transplants, found similar results whether donated organ came from person with or without AIDS ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, say global health specialists ...

Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

For the last year, it’s been legal in Missouri to use a tool that tests other drugs for the presence of fentanyl, a very ...